Second wave of late-phase Covid-19 vaccine trials unlikely to require a higher efficacy bar for FDA authorisation

Covid-19
The FDA is likely to face pressure to raise the efficacy bar for an authorization if there are one or two Covid-19 vaccines with an EUA. Credit: Shutterstock.